Your browser doesn't support javascript.
loading
Explainable artificial intelligence in skin cancer recognition: A systematic review.
Hauser, Katja; Kurz, Alexander; Haggenmüller, Sarah; Maron, Roman C; von Kalle, Christof; Utikal, Jochen S; Meier, Friedegund; Hobelsberger, Sarah; Gellrich, Frank F; Sergon, Mildred; Hauschild, Axel; French, Lars E; Heinzerling, Lucie; Schlager, Justin G; Ghoreschi, Kamran; Schlaak, Max; Hilke, Franz J; Poch, Gabriela; Kutzner, Heinz; Berking, Carola; Heppt, Markus V; Erdmann, Michael; Haferkamp, Sebastian; Schadendorf, Dirk; Sondermann, Wiebke; Goebeler, Matthias; Schilling, Bastian; Kather, Jakob N; Fröhling, Stefan; Lipka, Daniel B; Hekler, Achim; Krieghoff-Henning, Eva; Brinker, Titus J.
Affiliation
  • Hauser K; Digital Biomarkers for Oncology Group, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Kurz A; Digital Biomarkers for Oncology Group, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Haggenmüller S; Digital Biomarkers for Oncology Group, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Maron RC; Digital Biomarkers for Oncology Group, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • von Kalle C; Department of Clinical-Translational Sciences, Charité University Medicine and Berlin Institute of Health (BIH), Berlin, Germany.
  • Utikal JS; Department of Dermatology, Heidelberg University, Mannheim, Germany; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Meier F; Skin Cancer Center at the University Cancer Centre and National Center for Tumor Diseases Dresden, Department of Dermatology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany.
  • Hobelsberger S; Skin Cancer Center at the University Cancer Centre and National Center for Tumor Diseases Dresden, Department of Dermatology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany.
  • Gellrich FF; Skin Cancer Center at the University Cancer Centre and National Center for Tumor Diseases Dresden, Department of Dermatology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany.
  • Sergon M; Skin Cancer Center at the University Cancer Centre and National Center for Tumor Diseases Dresden, Department of Dermatology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany.
  • Hauschild A; Department of Dermatology, University Hospital (UKSH), Kiel, Germany.
  • French LE; Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany; Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA.
  • Heinzerling L; Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany.
  • Schlager JG; Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany.
  • Ghoreschi K; Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Schlaak M; Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Hilke FJ; Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Poch G; Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Kutzner H; Dermatopathology Laboratory, Friedrichshafen, Germany.
  • Berking C; Department of Dermatology, University Hospital Erlangen, Comprehensive Cancer Center Erlangen - EMN, Friedrich-Alexander University Erlangen, Nuremberg, Germany.
  • Heppt MV; Department of Dermatology, University Hospital Erlangen, Comprehensive Cancer Center Erlangen - EMN, Friedrich-Alexander University Erlangen, Nuremberg, Germany.
  • Erdmann M; Department of Dermatology, University Hospital Erlangen, Comprehensive Cancer Center Erlangen - EMN, Friedrich-Alexander University Erlangen, Nuremberg, Germany.
  • Haferkamp S; Department of Dermatology, University Hospital Regensburg, Regensburg, Germany.
  • Schadendorf D; Department of Dermatology, University Hospital Essen, Essen, Germany.
  • Sondermann W; Department of Dermatology, University Hospital Essen, Essen, Germany.
  • Goebeler M; Department of Dermatology, University Hospital Würzburg, Würzburg, Germany.
  • Schilling B; Department of Dermatology, University Hospital Würzburg, Würzburg, Germany.
  • Kather JN; Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Fröhling S; National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Lipka DB; National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hekler A; Digital Biomarkers for Oncology Group, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Krieghoff-Henning E; Digital Biomarkers for Oncology Group, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Brinker TJ; Digital Biomarkers for Oncology Group, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: titus.brinker@dkfz.de.
Eur J Cancer ; 167: 54-69, 2022 05.
Article in En | MEDLINE | ID: mdl-35390650
ABSTRACT

BACKGROUND:

Due to their ability to solve complex problems, deep neural networks (DNNs) are becoming increasingly popular in medical applications. However, decision-making by such algorithms is essentially a black-box process that renders it difficult for physicians to judge whether the decisions are reliable. The use of explainable artificial intelligence (XAI) is often suggested as a solution to this problem. We investigate how XAI is used for skin cancer detection how is it used during the development of new DNNs? What kinds of visualisations are commonly used? Are there systematic evaluations of XAI with dermatologists or dermatopathologists?

METHODS:

Google Scholar, PubMed, IEEE Explore, Science Direct and Scopus were searched for peer-reviewed studies published between January 2017 and October 2021 applying XAI to dermatological images the search terms histopathological image, whole-slide image, clinical image, dermoscopic image, skin, dermatology, explainable, interpretable and XAI were used in various combinations. Only studies concerned with skin cancer were included.

RESULTS:

37 publications fulfilled our inclusion criteria. Most studies (19/37) simply applied existing XAI methods to their classifier to interpret its decision-making. Some studies (4/37) proposed new XAI methods or improved upon existing techniques. 14/37 studies addressed specific questions such as bias detection and impact of XAI on man-machine-interactions. However, only three of them evaluated the performance and confidence of humans using CAD systems with XAI.

CONCLUSION:

XAI is commonly applied during the development of DNNs for skin cancer detection. However, a systematic and rigorous evaluation of its usefulness in this scenario is lacking.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Artificial Intelligence Type of study: Diagnostic_studies / Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: Eur J Cancer Year: 2022 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Artificial Intelligence Type of study: Diagnostic_studies / Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: Eur J Cancer Year: 2022 Document type: Article Affiliation country: